A Blueprint for Catalytic Promiscuity in de novo Designed Enzymes

1:00pm - 2:00pm / Monday 11th November 2019 / Venue: LT1 Life Sciences Building
Type: Seminar / Category: Research / Series: GSTT Seminar Series
  • Suitable for: Those with an interest in Genomes, Systems and Therapeutic Targeting
  • Admission: Free
  • Add this event to my calendar
    (?)

    When you click on "Add this event to my calendar" your browser will download an ics file.

    Microsoft Outlook: Download the file, then you may be able to click on "Save & Close" to save it to your calendar. If that doesn't work go into Outlook, click on the File tab, then on Open, then Import. Select "Import an iCalendar (.ic or vCalendar file (.vcs)" then click on Next. Find the .ics file and click on OK.

    Google Calendar: download the file, then go into your calendar. On the right where it says "Other calendars" click on the arrow icon and then click on Import calendar. Click on Browse and select the .ics file, then click on Import.

    Apple Calendar: download the file, then you can either drag it to Calendar or import the file by going to File > Import > Import and choosing the .ics file.

Speaker: Ross Anderson (University of Bristol)

Bespoke protein catalysts compatible with the natural biomolecular components of living cells are key to realizing the ambitious goals of synthetic biology and to the provision of cheap, green catalysts for industrial biotechnology. To this end, I believe that simple, de novo proteins naïve to the evolutionary process can provide excellent scaffolds for enzyme design, and here I highlight the work of my lab in constructing heme-containing de novo proteins that exhibit both biologically relevant and abiotic catalytic activities that equal and surpass those of many natural and engineered enzymes. I will show how a relatively simple design process is sufficient to create C45, a thermostable, artificial c-type cytochrome with exceptionally diverse catalytic activities – including peroxidase, oxidative dehalogenase and carbene transferase activities – that is fully assembled and catalytically active in vivo. Since C45 exhibits a high tolerance to organic solvents, I will also highlight my group’s work in encapsulating C45 into hydrogel beads, producing a versatile heterogeneous catalyst formulation that maintains the enzymatic activity of the de novo enzyme even in neat non-polar organic solvents. Finally, I will describe our recent design of b-type heme-containing proteins, demonstrating how fundamental biophysical properties such as redox potential can be successfully and precisely selected in silico.